Logo image of CDIO

CARDIO DIAGNOSTICS HOLDINGS (CDIO) Stock Fundamental Analysis

NASDAQ:CDIO - Nasdaq - US14159C1036 - Common Stock - Currency: USD

0.5045  +0.03 (+7.11%)

After market: 0.52 +0.02 (+3.07%)

Fundamental Rating

3

Overall CDIO gets a fundamental rating of 3 out of 10. We evaluated CDIO against 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CDIO as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, CDIO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CDIO had negative earnings in the past year.
CDIO had a negative operating cash flow in the past year.
CDIO Yearly Net Income VS EBIT VS OCF VS FCFCDIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -2M -4M -6M -8M

1.2 Ratios

CDIO has a worse Return On Assets (-184.16%) than 89.17% of its industry peers.
Looking at the Return On Equity, with a value of -223.89%, CDIO is doing worse than 70.52% of the companies in the same industry.
Industry RankSector Rank
ROA -184.16%
ROE -223.89%
ROIC N/A
ROA(3y)-106.21%
ROA(5y)N/A
ROE(3y)-149.83%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CDIO Yearly ROA, ROE, ROICCDIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -200 -400 -600 -800 -1K

1.3 Margins

CDIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDIO Yearly Profit, Operating, Gross MarginsCDIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -10K -20K -30K -40K

More info and screens

7

2. Health

2.1 Basic Checks

CDIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CDIO has been increased compared to 1 year ago.
Compared to 1 year ago, CDIO has an improved debt to assets ratio.
CDIO Yearly Shares OutstandingCDIO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 5M 10M 15M 20M
CDIO Yearly Total Debt VS Total AssetsCDIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2M 4M 6M

2.2 Solvency

CDIO has an Altman-Z score of 2.19. This is not the best score and indicates that CDIO is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.19, CDIO is doing good in the industry, outperforming 71.94% of the companies in the same industry.
There is no outstanding debt for CDIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.19
ROIC/WACCN/A
WACC9.4%
CDIO Yearly LT Debt VS Equity VS FCFCDIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 2M -2M 4M -4M -6M

2.3 Liquidity

A Current Ratio of 8.51 indicates that CDIO has no problem at all paying its short term obligations.
CDIO has a Current ratio of 8.51. This is in the better half of the industry: CDIO outperforms 74.25% of its industry peers.
CDIO has a Quick Ratio of 8.51. This indicates that CDIO is financially healthy and has no problem in meeting its short term obligations.
CDIO has a Quick ratio of 8.51. This is in the better half of the industry: CDIO outperforms 74.42% of its industry peers.
Industry RankSector Rank
Current Ratio 8.51
Quick Ratio 8.51
CDIO Yearly Current Assets VS Current LiabilitesCDIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 1M 2M 3M 4M 5M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.33% over the past year.
Looking at the last year, CDIO shows a very strong growth in Revenue. The Revenue has grown by 256.90%.
EPS 1Y (TTM)57.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
Revenue 1Y (TTM)256.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-34.4%

3.2 Future

CDIO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.03% yearly.
CDIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 467.90% yearly.
EPS Next Y44.36%
EPS Next 2Y27.03%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-59.71%
Revenue Next 2Y96.12%
Revenue Next 3Y467.9%
Revenue Next 5YN/A

3.3 Evolution

CDIO Yearly Revenue VS EstimatesCDIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
CDIO Yearly EPS VS EstimatesCDIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CDIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CDIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDIO Price Earnings VS Forward Price EarningsCDIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDIO Per share dataCDIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3

4.3 Compensation for Growth

A more expensive valuation may be justified as CDIO's earnings are expected to grow with 27.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.03%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CDIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDIO DIAGNOSTICS HOLDINGS

NASDAQ:CDIO (2/21/2025, 8:06:34 PM)

After market: 0.52 +0.02 (+3.07%)

0.5045

+0.03 (+7.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)04-01 2025-04-01/amc
Inst Owners4.93%
Inst Owner Change54.24%
Ins Owners4.52%
Ins Owner Change19.47%
Market Cap20.40M
Analysts82.86
Price Target2.04 (304.36%)
Short Float %4.84%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)43.85%
Min EPS beat(2)41.18%
Max EPS beat(2)46.52%
EPS beat(4)3
Avg EPS beat(4)17.46%
Min EPS beat(4)-117.86%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)6.02%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-93.5%
Min Revenue beat(2)-93.86%
Max Revenue beat(2)-93.14%
Revenue beat(4)0
Avg Revenue beat(4)-88.42%
Min Revenue beat(4)-97.92%
Max Revenue beat(4)-68.76%
Revenue beat(8)0
Avg Revenue beat(8)-92.79%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)45.45%
EPS NQ rev (3m)52%
EPS NY rev (1m)20.88%
EPS NY rev (3m)20.88%
Revenue NQ rev (1m)-86.67%
Revenue NQ rev (3m)-91.67%
Revenue NY rev (1m)-84.93%
Revenue NY rev (3m)-85.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 571.64
P/FCF N/A
P/OCF N/A
P/B 5.53
P/tB 6.74
EV/EBITDA N/A
EPS(TTM)-0.32
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS0
BVpS0.09
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -184.16%
ROE -223.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-106.21%
ROA(5y)N/A
ROE(3y)-149.83%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 360.37%
Cap/Sales 2560.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.51
Quick Ratio 8.51
Altman-Z 2.19
F-Score5
WACC9.4%
ROIC/WACCN/A
Cap/Depr(3y)553.87%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
EPS Next Y44.36%
EPS Next 2Y27.03%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)256.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-34.4%
Revenue Next Year-59.71%
Revenue Next 2Y96.12%
Revenue Next 3Y467.9%
Revenue Next 5YN/A
EBIT growth 1Y-3.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-169.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-141.23%
OCF growth 3YN/A
OCF growth 5YN/A